US2020181256A1PendingUtilityA1
Anti sez6 antibodies and methods of use
Est. expiryFeb 24, 2032(~5.6 yrs left)· nominal 20-yr term from priority
C07K 16/28A61K 39/00A61K 9/141A61P 35/00A61K 47/50C07K 2317/565C07K 2317/77A61K 47/6849A61K 39/395C07K 2317/76C07K 2317/24C07K 2317/33A61K 2039/505C12N 15/11
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Claims
exact text as granted — not AI-modified1 .- 20 . (canceled)
21 . A monoclonal antibody that comprises or competes for binding to a human SEZ6 protein with an antibody comprising a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 190 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 191.
22 . The monoclonal antibody according to claim 21 , wherein said antibody is an internalizing antibody.
23 . The monoclonal antibody according to claim 21 , wherein the antibody comprises a chimeric antibody, a CDR grafted antibody, or a humanized antibody.
24 . The monoclonal antibody according to claim 22 , wherein the antibody comprises a chimeric antibody, a CDR grafted antibody, or a humanized antibody.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.